We are delighted to welcome Dr Chloe Choi to the National Centre for Asbestos Related Diseases (NCARD) as a Research Associate. Dr Choi’s expertise in immunometabolism and natural killer (NK) cell biology will support the expansion of our Antigen Targeted Therapy Against Cancer (ATTAC) program to childhood cancers.
Dr Choi recently worked as a Technical Support Specialist at Abbott’s Diagnostic Division in Ireland. There, she focused on diagnostic assay development, data analysis, and laboratory troubleshooting – skills she brings to NCARD’s translational research efforts.
Dr Choi completed her PhD in Immunometabolism at Trinity College Dublin under Associate Professor David Finlay. Her research investigated how oxysterols – cholesterol-derived metabolites – affect NK cell metabolism and function within the tumour microenvironment. This work helped explain some of the challenges immunotherapy faces in treating solid tumours and has been published in journals including Nature Communications and Blood Advances.
Her technical experience includes multiparametric flow cytometry, qRT-PCR, ELISA, Western blotting, cytotoxicity assays, live cell imaging, and metabolic flux analysis. She has worked extensively with both murine and human NK cells.
Dr Choi holds a Bachelor of Science with Honours in Immunology from Trinity College Dublin. She received the highest marks for laboratory practical work in her cohort, earning her a funded internship. Throughout her training, she has mentored undergraduate and PhD students in laboratory techniques and data analysis.
At NCARD, Dr Choi will help adapt the ATTAC platform for use in paediatric cancers, working with Perth Children’s Hospital. ATTAC identifies cancer-specific markers (neoantigens) to support the development of targeted immunotherapies. Early results have shown promise in paediatric leukaemia.
Dr. Choi’s research into immune metabolism will help address why immunotherapy has been less effective in childhood cancers. Her work will contribute to developing immunotherapy strategies that are both effective and minimise long-term treatment side effects.
“I am thrilled to join NCARD and contribute to translating innovative immunotherapy approaches to childhood cancers. My passion for turning bench research into meaningful patient outcomes aligns with NCARD’s mission. Understanding how immune cells function in different tumour environments is crucial for developing better treatments.”
Dr Chloe Choi, NCARD
Dr. Choi’s appointment strengthens NCARD’s expertise in immunotherapy research. Her technical skills and focus on collaborative science will support NCARD in advancing cancer treatments for people of all ages.
Please join us in welcoming Dr Chloe Choi to the NCARD team.
